Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells
Metrics: PDF 1940 views | HTML 2656 views | ?
Lana Bruney1,2, Yueying Liu2,3, Anne Grisoli2, Matthew J. Ravosa4, M. Sharon Stack1,2,3
1Department of Medical Physiology & Pharmacology, University of Missouri School of Medicine, Columbia, MO, USA
2Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA
3Departments of Chemistry & Biochemistry and University of Notre Dame, Notre Dame, IN, USA
4Biological Sciences, University of Notre Dame, Notre Dame, IN, USA
M. Sharon Stack, e-mail: [email protected]
Keywords: integrin linked kinase, ovarian cancer, integrin, membrane type 1 matrix metalloproteinase, metastasis
Received: January 07, 2016 Accepted: February 20, 2016 Published: March 03, 2016
Epithelial ovarian cancer (EOC) is the most fatal gynecologic cancer in the U.S., resulting in >14,000 deaths/year. Most women are diagnosed at late stage with widely disseminated intra-peritoneal metastatic disease, resulting in a 5-year survival rate of <30%. EOCs spread via direct extension and exfoliation into the peritoneal cavity, adhesion to peritoneal mesothelial cells, mesothelial cell retraction to expose sub-mseothelial matrix and anchoring in the type I collagen-rich matrix to generate secondary lesions. As a molecular-level understanding of EOC metastasis may identify novel therapeutic targets, the current study evaluated the expression and activity of integrin-linked kinase (ILK), a Ser/Thr protein kinase activated upon integrin-mediated adhesion. Results show that ILK is co-expressed in EOC with the pro-metastatic enzyme membrane type 1 matrix metalloproteinase (MT1-MMP) and catalyzed phosphorylation of the cytoplasmic tail of the proteinase. Downregulation of ILK expression or activity reduced adhesion to and invasion of collagen gels and organotypic meso-mimetic cultures. As an initial early event in EOC metastasis is integrin-mediated adhesion, these results suggest that further evaluation of ILK inhibitors as anti-metastatic agents in EOC is warranted.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.